APA (7th ed.) Citation

CL, K., A, v. T., JE, G., B, H., G, L. M., A, B., . . . JD, I. (2023). EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the rheumatic diseases, 82(1), 65. https://doi.org/10.1136/annrheumdis-2022-222155

Chicago Style (17th ed.) Citation

CL, Krieckaert, et al. "EULAR Points to Consider for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Rheumatic and Musculoskeletal Diseases." Annals of the Rheumatic Diseases 82, no. 1 (2023): 65. https://doi.org/10.1136/annrheumdis-2022-222155.

MLA (9th ed.) Citation

CL, Krieckaert, et al. "EULAR Points to Consider for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Rheumatic and Musculoskeletal Diseases." Annals of the Rheumatic Diseases, vol. 82, no. 1, 2023, p. 65, https://doi.org/10.1136/annrheumdis-2022-222155.